Get the Stockscreener App
73.09
1.18%
-0.87
Ionis Pharmaceuticals Inc stock is traded at $73.09, with a volume of 1.80M.
It is down -1.18% in the last 24 hours and down -1.54% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
See More
Previous Close:
$73.96
Open:
$73.93
24h Volume:
1.80M
Relative Volume:
0.97
Market Cap:
$12.08B
Revenue:
$1.06B
Net Income/Loss:
$-326.58M
P/E Ratio:
-34.77
EPS:
-2.1022
Net Cash Flow:
$-977.73M
1W Performance:
-2.00%
1M Performance:
-1.54%
6M Performance:
-6.74%
1Y Performance:
+107.41%
1-Day Range:
$72.30
$73.95
1-Week Range:
$72.30
$75.85
52-Week Range:
$34.84
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
73.09 | 12.22B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Apr-10-26 | Resumed | Raymond James | Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Liquidity Mapping Around (IONS) Price Events - Stock Traders Daily
IONS Reiterated by TD Cowen -- Price Target Maintained at $108 - GuruFocus
Ionis Pharmaceuticals Stock (US46120E6023): Analyst updates keep biotech in focus - AD HOC NEWS
Insider plans 8,000-share sale at IONS (NASDAQ: IONS) on 06/15/2026 - Stock Titan
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
IONS (IONS) files Form 144 listing option-exercise shares on Nasdaq - Stock Titan
Ionis Highlights Positive Long-Term Olezarsen Data in Hypertriglyceridemia - TipRanks
Olezarsen liver fat study data highlighted by Ionis (NASDAQ: IONS) - Stock Titan
Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
GSK, Ionis mark late-stage trial win for chronic hepatitis B therapy - MSN
Ionis Pharmaceuticals touts $3B TRYNGOLZA opportunity, pipeline readouts at conference - MSN
Franklin Resources Inc. Has $104.53 Million Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Norges Bank Invests $25.33 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Sells 21,021 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Adds Veteran Leader to Board - The Globe and Mail
Ionis Pharmaceuticals, Inc. (IONS) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IONS) 2026-06-08 - Seeking Alpha
Ionis Pharmaceuticals (NASDAQ: IONS) director Peter Reikes files baseline Form 3 - Stock Titan
Ionis Pharmaceuticals adds Ludwig Hantson to board By Investing.com - Investing.com South Africa
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors - Lelezard
Ionis Pharmaceuticals adds Ludwig Hantson to board - Investing.com
Ionis’ ASO for ultra-rare neurological disorder awaits FDA’s decision - BioXconomy
CenterBook Partners LP Acquires Shares of 153,949 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital World Investors Has $1.42 Billion Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis updates time for fourth quarter and full year 2025 financial results webcast - Business Wire
Long term debt to total equity ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Debt to assets ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Price to book ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI - TradingView
Ionis Pharmaceuticals (IONS) Edges Lower Amidst Sector Headwinds; Key Support Levels in FocusVanna Flow - newsline.com
ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView
Ionis Pharmaceuticals, Inc. Balance Sheet – XETR:ISI - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – XETR:ISI - TradingView
Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline Updates - Yahoo Finance
TD Asset Management Inc Trims Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis (IONS) Q1 2026 Earnings Call Transcript - AOL.com
Arrowpoint Investment Partners Singapore Pte. Ltd. Acquires 19,554 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Key facts: Ionis licenses salanersen to Biogen; sees >$7B peak - TradingView
Why (IONS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
Ionis Pharmaceuticals Announces New Data on Olezarsen for sHTG T - GuruFocus
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses - standard-journal.com
Ionis Pharmaceuticals director sells $605,360 in stock - Investing.com UK
Ionis Pharmaceuticals director sells $605,360 in stock By Investing.com - Investing.com Canada
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Ionis Pharmaceuticals Insider Sold Shares Worth $605,360, According to a Recent SEC Filing - marketscreener.com
Geode Capital Management LLC Boosts Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
IONS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $125 - GuruFocus
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):